Prevalence and Factor Associated with Anti-N-Methyl-D-Aspartate Receptor Encephalitis Among Patients with Medical Conditions: A Systematic Review and Meta-Analysis.
Journal
Neurology India
ISSN: 1998-4022
Titre abrégé: Neurol India
Pays: India
ID NLM: 0042005
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
received:
03
07
2020
accepted:
27
04
2022
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe autoimmune encephalitis due to immune production of anti-NMDAR antibodies against the NR1 subunit of the NMDA receptor which is present throughout the central nervous system. This condition had been reported to be prevalent in patients with certain medical conditions; however so far, there have been limited systematic reviews and meta-analyses on the prevalence and factors associated. This study was to determine the prevalence and factors associated with anti-NMDAR encephalitis among affected patients. The protocol of this study has been registered (2019: CRD42019142002) with the International Prospective Register of Systematic Reviews (PROSPERO). The primary outcome was the incidence or prevalence of anti-NMDAR encephalitis and secondary outcomes were factors associated with anti-NMDAR encephalitis. There were 11 studies and a total of 873 million patients taken from high-risk populations across 11 countries that were included in the primary analysis. The overall pooled prevalence of anti-NMDAR encephalitis among patients with medical conditions was 7.0% (95% CI = 4.4, 9.6). Those with first episode of psychosis or schizophrenia were at a higher risk of developing anti-NMDAR encephalitis with an odds ratio of 5.976 (95% CI = 1.122, 31.825). We found that almost one-tenth of patients with medical conditions had anti-NMDAR encephalitis; particularly those with first episode of psychosis or schizophrenia were among the high-risk medical conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe autoimmune encephalitis due to immune production of anti-NMDAR antibodies against the NR1 subunit of the NMDA receptor which is present throughout the central nervous system. This condition had been reported to be prevalent in patients with certain medical conditions; however so far, there have been limited systematic reviews and meta-analyses on the prevalence and factors associated.
OBJECTIVE
OBJECTIVE
This study was to determine the prevalence and factors associated with anti-NMDAR encephalitis among affected patients.
MATERIAL AND METHODS
METHODS
The protocol of this study has been registered (2019: CRD42019142002) with the International Prospective Register of Systematic Reviews (PROSPERO). The primary outcome was the incidence or prevalence of anti-NMDAR encephalitis and secondary outcomes were factors associated with anti-NMDAR encephalitis.
RESULTS
RESULTS
There were 11 studies and a total of 873 million patients taken from high-risk populations across 11 countries that were included in the primary analysis. The overall pooled prevalence of anti-NMDAR encephalitis among patients with medical conditions was 7.0% (95% CI = 4.4, 9.6). Those with first episode of psychosis or schizophrenia were at a higher risk of developing anti-NMDAR encephalitis with an odds ratio of 5.976 (95% CI = 1.122, 31.825).
CONCLUSION
CONCLUSIONS
We found that almost one-tenth of patients with medical conditions had anti-NMDAR encephalitis; particularly those with first episode of psychosis or schizophrenia were among the high-risk medical conditions.
Identifiants
pubmed: 39041960
doi: 10.4103/neuroindia.NI_981_20
pii: 02223311-202405000-00003
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-486Informations de copyright
Copyright © 2024 Copyright: © 2024 Neurology India, Neurological Society of India.
Références
Ho AC-C, Chan SH-S, Chan E, Wong SS-N, Fung ST-H, Cherk SW-W, et al. Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong. Brain Dev 2018;40:473–9.
Ayubi E, Safiri S. Risk factors for mortality in patients with anti-NMDA receptor encephalitis; Comment on data sparsity. Acta Neurol Scand 2017;136:738.
Diamond B, Volpe BT. Antibodies and brain disease: A convergence of immunology and physiology. PLoS Med 2006;3:e498.
Keller S, Roitman P, Ben-Hur T, Bonne O, Lotan A. Anti-NMDA receptor encephalitis presenting as an acute psychotic episode in a young woman: An underdiagnosed yet treatable disorder. Case Rep Psychiatry 2014;2014:868325.
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.
DeSena AD, Greenberg BM, Graves D. Three phenotypes of Anti–N–Methyl-d-aspartate receptor antibody encephalitis in children: Prevalence of symptoms and prognosis. Pediatr Neurol 2014;51:542–9.
Luca N, Daengsuwan T, Dalmau J, Jones K, deVeber G, Kobayashi J, et al. Anti–N-methyl-D-aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. Arthritis Rheum 2011;63:2516–22.
Feigin RD, Cherry JD. Textbook of Pediatric Infectious Diseases. WB Saunders; 1998.
Ryan N. Anti-N-methyl-D-aspartate receptor-mediated encephalitis: Recent advances in diagnosis and treatment in children. Curr Prob Pediatr Ad 2016;46:58–61.
Gable M, Gavali S, Radner A, Tilley D, Lee B, Dyner L, et al. Anti-NMDA receptor encephalitis: Report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol 2009;28:1421–9.
Cundiff CA, Elawabdeh N, Naguib MM, Jactel SN, El Demellawy D, Abramowsky CR, et al. Does MAP2 have a role in predicting the development of anti-NMDAR encephalitis associated with benign ovarian teratoma? A report of six new pediatric cases. Pediatr Devel Pathol 2015;18:122–6.
Malter MP, Elger CE, Surges R. Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis. Seizure 2013;22:136–40.
Suh-Lailam BB, Haven TR, Copple SS, Knapp D, Jaskowski TD, Tebo AE. Anti-NMDA-receptor antibody encephalitis: Performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay. Clin Chim Acta 2013;421:1–6.
Thompson C, Kneen R, Riordan A, Kelly D, Pollard AJ. Encephalitis in children. Arch Dis Childhood 2012;97:150–61.
Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: Correlation with autoantibody types. J Neurol 2013;260:2744–53.
Solnes LB, Jones KM, Rowe SP, Pattanayak P, Nalluri A, Venkatesan A, et al. Diagnostic value of 18F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med 2017;58:1307–13.
Bykowski J, Kruk P, Gold JJ, Glaser CA, Sheriff H, Crawford JR. Acute pediatric encephalitis neuroimaging: Single-institution series as part of the California encephalitis project. Pediatr Neurol 2015;52:606–14.
Wingfield T, McHugh C, Vas A, Richardson A, Wilkins E, Bonington A, et al. Autoimmune encephalitis: A case series and comprehensive review of the literature. Qjm-Int J Med 2011;104:921–31.
Irani SR, Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci 2011;11:298–304.
Jeannin-Mayer S, André-Obadia N, Rosenberg S, Boutet C, Honnorat J, Antoine J, et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin Neurophysiol 2019;130:289–96.
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79:1094–100.
Zhang Y, Liu G, Di Jiang M, Li LP, Su YY. Analysis of electroencephalogram characteristics of anti-NMDA receptor encephalitis patients in China. Clin Neurophysiol 2017;128:1227–33.
Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008;47:303–27.
Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol-Neuroimmunol 2015;2:e130.
Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: A systematic review. Expert Rev Neurother 2015;15:1391–419.
Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosur Psychiatry 2008;79:324–6.
Kashyape P, Taylor E, Ng J, Krishnakumar D, Kirkham F, Whitney A. Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: The need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol 2012;16:74–8.
Ishiura H, Matsuda S, Higashihara M, Hasegawa M, Hida A, Hanajima R, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008;71:1921–3.
Agrawal S, Vincent A, Jacobson L, Milford D, Gupta R, Wassmer E. Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation. Arch Dis Child 2010;95:312.
Smith JH, Dhamija R, Moseley BD, Sandroni P, Lucchinetti CF, Lennon VA, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: Treatment response to plasmapheresis. Arch Neurol 2011;68:1069–72.
Ikeguchi R, Shibuya K, Akiyama S, Hino S, Kubo H, Takeda T, et al. Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis. Intern Med 2012;51:1585–9.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;12:157–65.
Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: A case-control study. Lancet Psychiatry 2017;4:42–8.
Berna F, Séverac F, Sauleau E-A, Meyer N, Weibel S. NMDAR antibodies in first episode psychosis: Conclusions too inflammatory given results? Lancet Psychiatry 2017;4:356–7.
Finke C, Bartels F, Lütt A, Prüss H, Harms L. High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients. J Neurol 2017;264:1968–77.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med 2007;4:e297.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012;49:1–15.
Ando Y, Shimazaki H, Shiota K, Tetsuka S, Nakao K, Shimada T, et al. Prevalence of elevated serum anti-N-methyl-D-aspartate receptor antibody titers in patients presenting exclusively with psychiatric symptoms: A comparative follow-up study. BMC Psychiatry 2016;16:226.
Jones HF, Mohammad SS, Reed PW, Dunn PP, Steele RH, Dale RC, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Māori and Pacific Island children in New Zealand. Dev Med Child Neurol 2017;59:719–24.
Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis. Lancet Neurol 2018;17:760–72.
Westman G, Sohrabian A, Aurelius E, Ahlm C, Schliamser S, Sund F, et al. Clinical significance of IgM and IgA class anti-NMDAR antibodies in herpes simplex encephalitis. J Clin Virol 2018;103:75–80.
Hsu M-H, Huang C-C, Hung P-L, Huang H-M, Huang L-T, Huang C-C, et al. Paraneoplastic neurological disorders in children with benign ovarian tumors. Brain Dev 2014;36:248–53.
Çoban A, İsmail Küçükali C, Bilgiç B, Yalçınkaya N, Haytural H, Ulusoy C, et al. Evaluation of incidence and clinical features of antibody-associated autoimmune encephalitis mimicking dementia. Behav Neurol 2014;2014:935379.
Jiménez-Valverde A, Lobo J, Hortal J. The effect of prevalence and its interaction with sample size on the reliability of species distribution models. Community Ecol 2009;10:196–205.
Hanley DF, Johnson RT, Whitley RJ. Yes, brain biopsy should be a prerequisite for herpes simplex encephalitis treatment. Arch Neurol 1987;44:1289–90.
Levitz RE. Herpes simplex encephalitis: A review. Heart Lung 1998;27:209–12.
Whitley RJ, Gnann JW. Viral encephalitis: Familiar infections and emerging pathogens. Lancet 2002;359:507–13.
Huppatz C, Durrheim DN, Levi C, Dalton C, Williams D, Clements MS, et al. Etiology of encephalitis in Australia, 1990–2007. Emerg Infect Dis 2009;15:1359–65.
Corey L, Stone EF, Whitley R, Mohan K. Difference between herpes simplex virus type I and type 2 neonatal encephalitis in neurological outcome. Lancet 1988;331:1–4.
Whitley RJ. Herpes simplex encephalitis: Adolescents and adults. Antivir Res 2006;71:141–8.
Khoo CS, Tan HJ, Osman SS. A case of Herpes Simplex Virus Type 1 (HSV-1) encephalitis as a possible complication of cosmetic nasal dermal filler injection. Am J Med Case Rep 2018;19:825–8.
Nguyen I, Urbanczyk K, Mtui E, Li S. Intracranial CNS Infections: A Literature Review and Radiology Case Studies. Semin Ultrasound Ct. Elsevier; 2019.
Kip E, Staal J, Tima H, Verstrepen L, Romano M, Lemeire K, et al. Inhibition of MALT1 decreases neuroinflammation and pathogenicity of virulent rabies virus in mice. J Virol 2018;92:e00720–18.
Iyaswamy A, Kammella AK, Thavasimuthu C, Wankupar W, Dapkupar W, Shanmugam S, et al. Oxidative stress evoked damages leading to attenuated memory and inhibition of NMDAR–CaMKII–ERK/CREB signalling on consumption of aspartame in rat model. J Food Drug Anal 2018;26:903–16.
Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+T cells in immunity to viruses. Nat Rev Immunol 2012;12:136–48.
Ikemoto K, Pollard RB, Fukumoto T, Morimatsu M, Suzuki F. Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. J Immunol Res 1995;155:1326–33.
Siao P, Kaku M. A Clinician’s Approach to Peripheral Neuropathy. Seminars in Neurology. Thieme Medical Publishers; 2019.
Geng G, Yu X, Jiang J, Yu X. Aetiology and pathogenesis of paraneoplastic autoimmune disorders. Autoimmun Rev 2020;19:102422.
Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M. Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 2018;23:118–20.
Matsuoka H, Kimura H, Koba H, Tambo Y, Ohkura N, Hara J, et al. Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 2018;19:e597–9.
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019;16:535–48.
Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999;340:1788–95.
Gable M, Glaser C. Anti-N-Methyl-d-Aspartate receptor encephalitis appearing as a new-onset psychosis: Disease course in children and adolescents within the California encephalitis project. Pediatr Neurol 2017;72:25–30.
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899–904.